search results for 
Logo

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. Approximately 150,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

Fresenius Medical Care

In 2011, we once again achieved strong results both in sales and in earnings. We have successfully met the challenges of the new reimbursement scheme in the United States. In addition, we are substantially growing our leading position in the global dialysis market through acquisitions and cooperations.

Fresenius Kabi

Our business grew once again in all regions and product segments. In North America, we even exceeded the strong 2010 results. In the emerging markets, we again achieved high growth rates. We have introduced products all over the world and increased our global market presence.

Fresenius Helios

2011 was a successful year with strong sales and earnings growth. Our established clinics achieved excellent operating results. With the acquisition of the maximum care hospital Katholisches Klinikum Duisburg and the announced acquisition of Damp Group, we continue our growth path within the German hospital market and strengthen our clinic network.

Fresenius Vamed

In 2011, sales and EBIT exceeded the strong previous year’s levels despite challenging market conditions in the Middle East / North Africa region. Order backlog reached a new all-time high. Order intake was again at an excellent level.

TO OUR SHAREHOLDERS

  

FRESENIUS SHARE 2011

  

KEY TOPICS

  

KEY FIGURES COMPARISON

Picture of Fresenius CEO I am pleased to report record results for sales and earnings for 2011. We increased Group sales in constant currency by 8 percent to €16.0 billion.

more... 		 

The Fresenius share successfully defended itself against the significant price turbulences and benefited from its relative indepen- dence from the greater economy. Fresenius Share more...

 

Summary of the fiscal year

Consolidated sales increased by 3% to € 16,522 million and operating income (EBIT) grew by 6% to € 2,563 million. Earnings per share rose by 16% to € 4.73.

more...

Strategy and Goals

Our goal is to build Fresenius into a leading global provider of products and therapies for critically and chronically ill people.

more...

Employees

Well-trained and experienced employees are an important prerequisite for our company success.

more...

Outlook

With its international production and sales platform and its market-oriented products and services, the Fresenius Group is well positioned for continued growth in the coming years.

more...
 

Fresenius Key Figures 2011 Use our interactive key figures comparison. Here you can compare individual key figures and show them as graphs.

more...